April 24, 2024
Amikacin Injection FDA does not recognize MI00 standard (MIC and disk diffusion) for Enterobacterales and Pseudomonas aeruginosa Antibacterial 4/21/2023 Amoxicillin and clavulanate Oral FDA does not […]
April 24, 2024
Due to the COVID-19 pandemic, FDA has been closely monitoring the medical product supply chain with the expectation that it may be impacted by the COVID-19 […]
April 24, 2024
For Immediate Release: April 24, 2024 Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary […]
April 24, 2024
An algorithm-driven risk assessment embedded in an electronic health record (EHR) helped clinicians reduce inappropriate broad-spectrum antibiotic prescribing by 17.4% and 28.4% in patients with UTIs […]
April 24, 2024
TOPLINE: Decreased total sleep time (TST) and increased resting heart rate (RHR), heart rate variability (HRV), and average nightly respiratory rate (ARR) as measured by a […]
April 24, 2024
Immunization with inactivated vaccines while receiving the disease-modifying therapy natalizumab for highly active multiple sclerosis (MS) is safe and immunogenic, with no increased risk for disease […]
April 24, 2024
Should you find a Web link (URL) embedded within guidance documents that does not work or other documents posted on the FDA Web site, please try […]
April 24, 2024
BOSTON — The severity of treatment-resistant depression (TRD) appears to predict response to intravenous (IV) ketamine vs electroconvulsive therapy (ECT), new research suggested. However, experts said […]
April 24, 2024
An abbreviated new drug application (ANDA) contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, […]